Skin AgingNCT07774117
CyanthOx™ Capsule Efficacy Study
A study testing CyanthOx™80 Group in people with Skin Aging and Hair and Scalp Health, run by Chia Nan University of Pharmacy ＆ Science at 1 site in Taiwan.
Trial summary
The goal of this clinical trial is to learn whether daily intake of CyanthOx™80 capsules can improve skin, scalp, hair, and selected blood biomarkers in healthy adults after 12 weeks. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Aging, Hair and Scalp Health, Hair Loss
- What is being tested?
- CyanthOx™80 Group
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Nov 2025to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants aged over 18 years.
Who cannot join
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
- Students taught by the principal investigator.
- Individuals unwilling to allow their study-related photographs to be disclosed. Vegetarians.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Study Plan for CyanthOx™ Hard Capsule
The goal of this clinical trial is to learn whether daily intake of CyanthOx™80 capsules can improve skin, scalp, hair, and selected blood biomarkers in healthy adults after 12 weeks.
Researchers will compare participants who take CyanthOx™80 with participants who take a placebo to evaluate its effectiveness and tolerability.
Read more
A total of 40 participants will be randomly assigned to the CyanthOx™80 group or placebo group, with 20 participants in each group. Participants will not know which capsule they receive.
Participants will:
Take one capsule daily for 12 weeks. Attend study visits at baseline and weeks 4, 8, and 12. Undergo non-invasive facial skin assessments at baseline, week 4, and week 12. Undergo scalp and hair assessments at baseline and weeks 4, 8, and 12. Provide a 10 mL blood sample at baseline and week 12 for tests related to antioxidant capacity, inflammation, aging, collagen, and blood lipids.
Complete questionnaires about skin condition and product satisfaction. Provide collected shed hair at weeks 4, 8, and 12. Have facial, scalp, and hair photographs taken. Identifiable areas will be masked before disclosure.
Before each skin or scalp assessment, participants will cleanse the test area with water and rest at room temperature for 30 minutes.
- Conditions
- Skin Aging, Hair and Scalp Health, Hair Loss
- Being tested
- Placebo Group, CyanthOx™80 Group
- Keywords
- Skin Health, Hair Health, Antioxidant Capacity
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo GroupDietary supplement
Participants will take one placebo capsule daily for 12 weeks.
CyanthOx™80 GroupDietary supplement
Participants will take one CyanthOx™80 capsule daily for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| CyanthOx™80 Group | Experimental | Participants will take one CyanthOx™80 capsule daily for 12 weeks. Receives: Dietary Supplement: CyanthOx™80 Group |
| Placebo Group | Placebo comparator | Participants will take one placebo capsule daily for 12 weeks. Receives: Dietary Supplement: Placebo Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Blood Biomarkers (TEAC)
Changes in biomarkers related to antioxidant capacity using TEAC ELISA kits. Unit: μM
Measured: Baseline and Week 12
Change in Hair and Scalp Condition (hair-root diameter)
Changes in hair-root diameter by using Mitutoyo, C/N293-100 Unit：percent change
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair strength)
Changes in hair strength by using Hair Pull Test Unit：percent change
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair elasticity)
Changes in hair elasticity measured using SHIMADZU EZ-SX Unit：percent change
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (tensile strength)
Changes in tensile strength by using SHIMADZU EZ-SX Unit：percent change
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair shedding)
Changes in hair shedding by collecting and counting hairs found in the shower drain unit：percent change
Measured: Baseline, Week 4, Week 8, and Week 12
Change in Blood Biomarkers (SOD)
Changes in biomarkers related to antioxidant capacity measured using SOD ELISA kits.
Unit: U/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (GSH)
Changes in biomarkers related to antioxidant capacity using GSH ELISA kits. Unit: ng/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (TNF-alpha)
Changes in biomarkers related to inflammation measured using TNF-alpha ELISA kits.
Unit: pg/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (Desmosine)
Changes in biomarkers related to aging measured using Desmosine ELISA kits. Unit: ng/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (AGE)
Changes in biomarkers related to aging measured using AGE ELISA kits. Unit: μg/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (HA)
Changes in biomarkers related to Hyaluronan content measured using HA kits. Unit: ng/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (NAD/NADH)
Changes in biomarkers related to antioxidant capacity measured using NAD/NADH ELISA kits.
Unit: μM/L
Measured: Baseline and Week 12
Change in Blood Biomarkers (Collagen)
Changes in biomarkers related to collagen metabolism measured using Collagen ELISA kits.
Unit: μg/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (Telomerase)
Changes in biomarkers related to aging, measured using Telomerase ELISA kits. Unit: ng/mL
Measured: Baseline and Week 12
Change in Blood Biomarkers (Total cholesterol)
Change in serum Total cholesterol levels measured using an automated clinical chemistry analyzer.
Unit: mg/dL
Measured: Baseline and Week 12
Change in Blood Biomarkers (TG)
Change in serum triglyceride levels measured using an automated clinical chemistry analyzer.
Unit: mg/dL
Measured: Baseline and Week 12
Change in Blood Biomarkers (HDL)
Change in serum high-density lipoprotein cholesterol (HDL-C) levels measured using an automated clinical chemistry analyzer.
Unit: mg/dL
Measured: Baseline and Week 12
Change in Blood Biomarkers (LDL)
Change in serum low-density lipoprotein cholesterol (LDL-C) levels measured using an automated clinical chemistry analyzer.
Unit: mg/dL
Measured: Baseline and Week 12
Facial Skin Analysis Parameters (skin spots)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Wrinkle)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Wrinkle. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Texture)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Texture. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (UV Spot)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure UV Spot. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Brown Spot)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Brown Spot. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Red Area)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Red Area. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Collagen)
DermaLab® Series SkinLab Combo was utilized to measure collagen. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Brightness)
Chroma Meter MM500 was utilized to measure Brightness. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Erythema)
Chroma Meter MM500 was utilized to measure Erythema. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Melanin)
Soft Plus was utilized to measure Melanin. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Skin Hydration)
Corneometer CM825 was utilized to measure Skin Hydration. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Skin Elasticity)
Soft Plus was utilized to measure Skin Elasticity. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Transepidermal Water Loss)
Tewameter TM300 was utilized to measure Transepidermal Water Loss. Units: percetage change.
Measured: Baseline, Week 4, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study start1 Nov 2025
- Primary completion31 Jan 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chia Nan University of Pharmacy ＆ Science
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07774117
- Sponsor's protocol ID
- TSMHIRB25-052-A
- Status last verified
- May 2025
- First submitted
- 5 Aug 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study Plan for CyanthOx™ Hard Capsule
- ClinicalTrials.gov ID
- NCT07774117
- Acronym / sponsor ID
- TSMHIRB25-052-A
- Conditions
- Skin Aging, Hair and Scalp Health, Hair Loss
- Keywords
- Skin Health, Hair Health, Antioxidant Capacity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Chia Nan University of Pharmacy ＆ ScienceUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 31 Jan 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether daily intake of CyanthOx™80 capsules can improve skin, scalp, hair, and selected blood biomarkers in healthy adults after 12 weeks.
Researchers will compare participants who take CyanthOx™80 with participants who take a placebo to evaluate its effectiveness and tolerability.
A total of 40 participants will be randomly assigned to the CyanthOx™80 group or placebo group, with 20 participants in each group. Participants will not know which capsule they receive.
Participants will:
Take one capsule daily for 12 weeks. Attend study visits at baseline and weeks 4, 8, and 12. Undergo non-invasive facial skin assessments at baseline, week 4, and week 12. Undergo scalp and hair assessments at baseline and weeks 4, 8, and 12. Provide a 10 mL blood sample at baseline and week 12 for tests related to antioxidant capacity, inflammation, aging, collagen, and blood lipids.
Complete questionnaires about skin condition and product satisfaction. Provide collected shed hair at weeks 4, 8, and 12. Have facial, scalp, and hair photographs taken. Identifiable areas will be masked before disclosure.
Before each skin or scalp assessment, participants will cleanse the test area with water and rest at room temperature for 30 minutes.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CyanthOx™80 Group | Experimental | Dietary Supplement: CyanthOx™80 GroupParticipants will take one CyanthOx™80 capsule daily for 12 weeks. |
| Placebo Group | Placebo comparator | Dietary Supplement: Placebo GroupParticipants will take one placebo capsule daily for 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Participants aged over 18 years.
Key exclusion criteria (7 listed)
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo GroupParticipants will take one placebo capsule daily for 12 weeks. | Dietary supplement | Placebo Group |
| CyanthOx™80 GroupParticipants will take one CyanthOx™80 capsule daily for 12 weeks. | Dietary supplement | CyanthOx™80 Group |
Primary outcome
Change in Blood Biomarkers (TEAC)
Time frame: Baseline and Week 12
Changes in biomarkers related to antioxidant capacity using TEAC ELISA kits. Unit: μM
Change in Hair and Scalp Condition (hair-root diameter)
Time frame: Baseline, Week 4, Week 8, and Week 12
Changes in hair-root diameter by using Mitutoyo, C/N293-100 Unit：percent change
Change in Hair and Scalp Condition (hair strength)
Time frame: Baseline, Week 4, Week 8, and Week 12
Changes in hair strength by using Hair Pull Test Unit：percent change
Change in Hair and Scalp Condition (hair elasticity)
Time frame: Baseline, Week 4, Week 8, and Week 12
Changes in hair elasticity measured using SHIMADZU EZ-SX Unit：percent change
Change in Hair and Scalp Condition (tensile strength)
Time frame: Baseline, Week 4, Week 8, and Week 12
Changes in tensile strength by using SHIMADZU EZ-SX Unit：percent change
Change in Hair and Scalp Condition (hair shedding)
Time frame: Baseline, Week 4, Week 8, and Week 12
Changes in hair shedding by collecting and counting hairs found in the shower drain unit：percent change
Change in Blood Biomarkers (SOD)
Time frame: Baseline and Week 12
Changes in biomarkers related to antioxidant capacity measured using SOD ELISA kits. Unit: U/mL
Change in Blood Biomarkers (GSH)
Time frame: Baseline and Week 12
Changes in biomarkers related to antioxidant capacity using GSH ELISA kits. Unit: ng/mL
Change in Blood Biomarkers (TNF-alpha)
Time frame: Baseline and Week 12
Changes in biomarkers related to inflammation measured using TNF-alpha ELISA kits. Unit: pg/mL
Change in Blood Biomarkers (Desmosine)
Time frame: Baseline and Week 12
Changes in biomarkers related to aging measured using Desmosine ELISA kits. Unit: ng/mL
Change in Blood Biomarkers (AGE)
Time frame: Baseline and Week 12
Changes in biomarkers related to aging measured using AGE ELISA kits. Unit: μg/mL
Change in Blood Biomarkers (HA)
Time frame: Baseline and Week 12
Changes in biomarkers related to Hyaluronan content measured using HA kits. Unit: ng/mL
Change in Blood Biomarkers (NAD/NADH)
Time frame: Baseline and Week 12
Changes in biomarkers related to antioxidant capacity measured using NAD/NADH ELISA kits. Unit: μM/L
Change in Blood Biomarkers (Collagen)
Time frame: Baseline and Week 12
Changes in biomarkers related to collagen metabolism measured using Collagen ELISA kits. Unit: μg/mL
Change in Blood Biomarkers (Telomerase)
Time frame: Baseline and Week 12
Changes in biomarkers related to aging, measured using Telomerase ELISA kits. Unit: ng/mL
Change in Blood Biomarkers (Total cholesterol)
Time frame: Baseline and Week 12
Change in serum Total cholesterol levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Change in Blood Biomarkers (TG)
Time frame: Baseline and Week 12
Change in serum triglyceride levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Change in Blood Biomarkers (HDL)
Time frame: Baseline and Week 12
Change in serum high-density lipoprotein cholesterol (HDL-C) levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Change in Blood Biomarkers (LDL)
Time frame: Baseline and Week 12
Change in serum low-density lipoprotein cholesterol (LDL-C) levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Facial Skin Analysis Parameters (skin spots)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots. Units: percetage change.
Facial Skin Analysis Parameters (Wrinkle)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Wrinkle. Units: percetage change.
Facial Skin Analysis Parameters (Texture)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Texture. Units: percetage change.
Facial Skin Analysis Parameters (UV Spot)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure UV Spot. Units: percetage change.
Facial Skin Analysis Parameters (Brown Spot)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Brown Spot. Units: percetage change.
Facial Skin Analysis Parameters (Red Area)
Time frame: Baseline, Week 4, and Week 12
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Red Area. Units: percetage change.
Facial Skin Analysis Parameters (Collagen)
Time frame: Baseline, Week 4, and Week 12
DermaLab® Series SkinLab Combo was utilized to measure collagen. Units: percetage change.
Facial Skin Analysis Parameters (Brightness)
Time frame: Baseline, Week 4, and Week 12
Chroma Meter MM500 was utilized to measure Brightness. Units: percetage change.
Facial Skin Analysis Parameters (Erythema)
Time frame: Baseline, Week 4, and Week 12
Chroma Meter MM500 was utilized to measure Erythema. Units: percetage change.
Facial Skin Analysis Parameters (Melanin)
Time frame: Baseline, Week 4, and Week 12
Soft Plus was utilized to measure Melanin. Units: percetage change.
Facial Skin Analysis Parameters (Skin Hydration)
Time frame: Baseline, Week 4, and Week 12
Corneometer CM825 was utilized to measure Skin Hydration. Units: percetage change.
Facial Skin Analysis Parameters (Skin Elasticity)
Time frame: Baseline, Week 4, and Week 12
Soft Plus was utilized to measure Skin Elasticity. Units: percetage change.
Facial Skin Analysis Parameters (Transepidermal Water Loss)
Time frame: Baseline, Week 4, and Week 12
Tewameter TM300 was utilized to measure Transepidermal Water Loss. Units: percetage change.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Skin Aging
Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
RecruitingPhase 3
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Skin Quality
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CyanthOx™80 Group in people with Skin Aging and Hair and Scalp Health, run by Chia Nan University of Pharmacy ＆ Science at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Blood Biomarkers (TEAC) (time frame: Baseline and Week 12). The study lists 32 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.